Altre lingue Pulmonx Corporation

Azioni

LUNG

US7458481014

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 05/07/2024			Variaz. 5gg	Var. 1 gen.
6,49 ^USD	+3,02%		+2,37%	-49,10%

04/06	PULMONX CORPORATION : Lake Street ancora positivo	ZM
01/05	Transcript : Pulmonx Corporation, Q1 2024 Earnings Call, May 01, 2024

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Pulmonx Corporation(NasdaqGS:LUNG) dropped from S&P Healthcare Equipment Select Industry Index	24/06
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	06/05
Pulmonx : Investor Presentation – May 2024	02/05
Earnings Flash (LUNG) PULMONX CORPORATION Posts Q1 Revenue $18.9M, vs. Street Est of $17.9M	01/05
Pulmonx Reports First Quarter 2024 Financial Results	01/05
Pulmonx Corporation Provides Revenue Guidance for the Full Year 2024	01/05
Pulmonx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05
Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024	10/04
Pulmonx Appoints Mehul Joshi as Chief Financial Officer	02/04
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer	02/04
Pulmonx Corporation Announces Chief Financial Officer Changes, Effective April 3, 2024	02/04
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	15/03
Pulmonx Announces Treatment of the First Patient with the AeriSeal System in CONVERT II Pivotal Trial	27/02
Pulmonx kondigt behandeling aan van de eerste patiënt met het AeriSeal®-systeem in de CONVERT II-studie	27/02
Pulmonx meldet Behandlung des ersten Patienten mit dem AeriSeal®-System in der CONVERT-II-Zulassungsstudie	27/02
Pulmonx annonce le traitement du premier patient par système AeriSeal® dans l'essai pivot CONVERT II	27/02
Pulmonx anuncia el tratamiento del primer paciente con el sistema AeriSeal® en el ensayo pivotal CONVERT II	27/02
Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial	26/02
Pulmonx Corporation Announces Treatment of the First Patient with the Aeriseal System in Convert II Pivotal Trial	26/02
North American Morning Briefing : Traders Await -2-	26/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Pulmonx Corporation

Azioni

LUNG

US7458481014

Altre lingue

Filtri